Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DTIL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPrecision BioSciences reports Q1 2026 financial results
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing financial results for quarter ended March 31, 2026. Actual figures are in the attached exhibit, not disclosed in the 8-K body itself.
Item 2.02 verify on EDGAR →
Summary
Precision BioSciences filed an 8-K to announce its first quarter 2026 financial results through a press release dated May 5, 2026. This is a routine earnings disclosure filing where the company formally notifies the SEC and investors of its quarterly performance. The actual financial figures, operational updates, and management commentary would be contained in the attached press release (Exhibit 99.1), which is not included in the 8-K body itself.
For retail investors, the key action item is to review the full press release to understand the company's Q1 performance, including revenue, cash position, and any updates on its gene editing pipeline programs. Watch for management's guidance on cash runway and clinical trial progress in the detailed release.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Precision BioSciences announced Q1 2026 financial results via press release on May 5, 2026.
Added in current filing · verify on EDGAR →
On May 5, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the press release as Exhibit 99.1. This is a standard earnings announcement filing where the detailed results would be in the attached exhibit.
Event · Item 9.01 — Financial Statements and Exhibits
Precision BioSciences filed an 8-K attaching a press release dated May 5, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press release of Precision BioSciences, Inc. dated May 5, 2026.
The 8-K references an attached press release dated May 5, 2026, but does not disclose the content or subject matter of the press release in the filing body. Without access to Exhibit 99.1, the nature and materiality of the announcement cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify